TABLE 4

Outcome-associated characteristics of 37 patients

VariableOutcomeUnivariate analysisMultivariable analysis
SurvivalDeathOR (95% CI)P valueaORa (95% CI)P value
Median age (yr)33 (28–36)35 (31–38)1.0 (0.9–1.2)0.59
Sex
    No. (%) of males15/23 (65.2)5/14 (35.7)ReferenceReference
    No. (%) of females8/23 (34.8)9/14 (64.3)3.4 (0.8–13.6)0.082.14 (0.44–10.36)0.34
Province
    Gauteng1/22 (4.6)4/12 (33.3)Reference
    Western Cape19/22 (86.4)8/12 (66.7)0.11 (0.01–1.1)0.06
    Eastern Cape*
    Free State2/22 (9.1)0/12 (0)
Median no. of CD4 cells/μl (IQR)13 (9–32)14 (6–27)1.0 (0.98–1.04)0.50
ART history
    No. naive/total (%)6/21 (28.6)3/10 (30)Reference
    No. experienced/total (%)15/21 (71.4)7/10 (70)0.93 (0.17–4.87)0.94
Any antifungal treatment
    No. without/total (%)0/22 (0)6/11 (54.6)Reference
    No. with/total (%)22/22 (100)5/11 (45.5)1
Specimen type
    No. of skin biopsy samples/total (%)15/23 (65.2)2/14 (14.3)ReferenceReference
    No. of blood cultures/total (%)6/23 (26.1)8/14 (57.1)10 (1.62–61.47)0.018.57 (1.35–54.33)0.02
    No. of bone marrow aspirates/total (%)2/23 (8.7)4/14 (28.6)15 (1.58–142.18)0.0212.1 (1.21–120.13)0.03
Antifungal MIC50
    Amphotericin Bb0.060.060.16 (0.001–20.82)0.47
    Posaconazolec0.0080.0081.91 (0.10–34.82)0.66
    Itraconazolec0.0080.0080.26 (0.0004–140.69)0.67
    Voriconazolec0.0080.00872.3 (9.89–5.30)0.87
    Fluconazolec0.120.200.75 (0.29–1.92)0.54
  • a aOR, adjusted OR.

  • b Determined by Etest, yeast phase.

  • c Determined by BMD, mold phase.